|Site||# in less developed regions||# in more developed regions||# in United States|
(Data from Table 4 in "Global burden of human papillomavirus and related diseases" and Table 2 in MMWR / April 20, 2012 / Vol. 61 / No. 15.)
Thus cervical cancer represents about 92% of HPV-caused cancer in less developed countries, about 65% in more developed countries, and about 55% in the United States.
Presumably the reason cervical cancer represents a lower percentage of HPV-caused cancers in the US is that we have a relatively successful cervical cancer screening program compared to less well developed countries, and that there is as yet no screening program for non-cervical HPV-caused cancers.
"The incidence rates for squamous carcinoma decreased by 61.1% from 10.2/100,000 (1973-1975) to 3.97/100,000 (2006-2007)."Examining the incidence of human papillomavirus-associated head and neck cancers by race and ethnicity in the U.S., 1995-2005" says
Incidence rates for adenosquamous cell carcinomas decreased by 16% from 0.27/100,000 (1973-1975) to 0.23/100,000 (2006-2007), and
incidence rates for adenocarcinomas increased by 32.2% from 1.09/100,000 (1973-1975) to 1.44/100,000 (2006-2007).
This increase in adenocarcinomas was due to an increase in incidence in white women; a decrease in incidence was observed for black women.
CONCLUSIONS: Although marked reductions in the overall and race-specific incidence rates of invasive cervical cancer have been achieved, they mask important variation by histologic subtype. These findings suggest that alternatives to Pap smear-based screening, such as human papillomavirus (HPV) testing and HPV vaccination, need to be prioritized if adenocarcinomas of the cervix are to be controlled."
for HPV-associated sites, HNC incidence for Non-Hispanic White males aged 45-54 increased at the greatest rate, with an APC of 6.28% (p<0.05)"Human papillomavirus and rising oropharyngeal cancer incidence in the United States" says
If recent incidence trends continue, the annual number of HPV-positive oropharyngeal cancers is expected to surpass the annual number of cervical cancers by the year 2020.